Gryaznov Sergei 4
4 · MAIA Biotechnology, Inc. · Filed Apr 14, 2026
Research Summary
AI-generated summary of this filing
MAIA CSO Sergei Gryaznov Receives 400,000-Share Option Award
What Happened
Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, was granted a derivative award on April 10, 2026 representing the right to acquire 400,000 shares of MAIA common stock. The Form 4 records the acquisition amount as $0.00, reflecting an option/grant rather than a cash purchase.
Key Details
- Transaction date: 2026-04-10; Form 4 filed 2026-04-14 (timely within two business days).
- Transaction type/code: A (award/grant of a derivative security — stock options).
- Shares/options: 400,000-option grant reported. Reported cash amount: $0.00.
- Vesting: 4-year schedule — 25% vests on the first anniversary, remaining options vest ratably monthly over the next 36 months (per footnote).
- Shares owned after transaction: not specified in the provided filing.
- No 10b5-1 plan, tax-withholding, cashless exercise, or sale reported in this filing.
Context
This was an equity compensation grant (options) intended for future vesting and not an immediate market purchase or sale. Such grants are typically part of executive compensation and retention; they do not represent an immediate cash investment or disposition by the insider.
Insider Transaction Report
Form 4
Gryaznov Sergei
Chief Scientific Officer
Transactions
- Award
Stock Options
[F1]2026-04-10+400,000→ 400,000 totalExercise: $1.28From: 2027-04-10Exp: 2036-04-10→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]The stock options, granted on April 10, 2026 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary date of the grant and the remaining options to vest ratably monthly thereafter for 36 months.
Signature
/s/ Sergei M. Gryaznov|2026-04-14